Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Leading healthcare information technology (“HCIT”) solutions provider, Cerner Corp. ( CERN - Analyst Report ) recently reported that it launched its positive patient identification (“PPID”) system to enhance medical outcomes at Corniche Hospital in the United Arab Emirates (“UAE”). The hospital is Cerner’s first customer in that country with a complete closed-loop medication administration system. Due to this system, drugs may be administered to the patient in congruence with established norms.
The PPID initiative uses bar code know-how with a hand-held instrument which reads from the wristband of the patient. It confirms data in the electronic health/medical record (“EHR/EMR”) of the patient operated by Cerner’s Millennium technology. This PPID program is in consonance with the benchmarks set by the Joint Commission International (“JCI”).
The closed loop medication system, to provide automated validation of drugs, has been launched in one nursing unit of the hospital. Corniche Hospital has been qualified for Stage 6 certification in the HIMSS Analytics EMR Adoption Model (“EMRAM”). Consequently, it was conferred with HIMSS 6 recognition at the EMRAM Awards Ceremony at the yearly HIMSS Mid East Conference and Leadership Summit held on May 20, at Abu Dhabi. The hospital is Cerner’s second customer, located in the Mid East, to achieve HIMSS Stage 6 qualification.
We believe long-term investors may consider Cerner, which serves a sizeable installed hospital base that requires composite clinically-focused applications complying with “meaningful use” requirements, reimbursement problems and complex coding issues. The company has long-standing, integrated and seamless solutions for both inpatient and ambulatory settings.
On the negative side, the federal Stimulus program will gradually wind down. Cerner faces stiff competition from established HCIT players, such as Athenahealth ( ATHN - Analyst Report ) , Allscripts-Misys ( MDRX - Analyst Report ) and Quality Systems ( QSII - Analyst Report ) and many others in a crowded field.
Read the full Analyst Report on CERN
Read the full Analyst Report on ATHN
Read the full Analyst Report on MDRX
Read the full Analyst Report on QSII